- Conditions
- Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
- Interventions
- Dulaglutide 0.75Mg/0.5Ml Inj Pen
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Abnormal Glucose Tolerance, Type 1 Diabetes
- Interventions
- CTLA4-Ig (Abatacept), Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Years to 45 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 16
- States / cities
- San Francisco, California • Stanford, California • Denver, Colorado + 12 more
- Conditions
- Impaired Glucose Tolerance, Insulin Resistance
- Interventions
- LIM-0705, Placebo capsules
- Drug
- Lead sponsor
- Limerick BioPharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Type1 Diabetes Mellitus
- Interventions
- Hydroxychloroquine, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 3 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 37
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 33 more
- Conditions
- Abnormal Glucose Tolerance
- Interventions
- WBF-0031
- Dietary Supplement
- Lead sponsor
- Eden Miller
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Bend, Oregon
- Conditions
- Cystic Fibrosis-related Diabetes
- Interventions
- Oral glucose tolerance test, Continuous glucose monitoring, Dexa scan
- Diagnostic Test
- Lead sponsor
- Katie Larson Ode
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Iowa City, Iowa • Minneapolis, Minnesota + 1 more
- Conditions
- Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF), Abnormal Glucose Tolerance
- Interventions
- Verapamil Hydrochloride
- Drug
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Providence, Rhode Island